Chrysanthemum indicum L. Extract Induces Apoptosis in Glioma Models

Study Background and Research Question

Gliomas remain among the most challenging primary brain tumors, with limited therapeutic options and poor prognosis. Traditional herbal medicines are increasingly recognized for their potential anticancer properties. Chrysanthemum indicum L., an herb with established anti-inflammatory and antitumor activities, is a key component of Jiawei Juming Decoction—a clinical formula used for glioma treatment in China. Despite its clinical relevance, the molecular mechanisms underlying Chrysanthemum indicum L.'s effect on glioma have not been systematically investigated. The reference study addresses this gap by integrating computational and experimental approaches to clarify how extracts from this plant impact glioma progression, particularly focusing on apoptosis induction and pathway modulation.

Key Innovation from the Reference Study

The central innovation of this work lies in its multi-layered methodology: combining network pharmacology, molecular docking, and both in vitro and in vivo experiments to map the anti-glioma activity of Chrysanthemum indicum L. extract (CIE). Unlike prior studies limited to phenomenological observations, this approach systematically identifies active compounds, predicts their protein targets, and validates mechanistic hypotheses in cellular and animal models. The authors' ability to pinpoint key molecular targets—such as the androgen receptor (AR)—and confirm direct interactions with CIE's phytochemicals distinguishes this research within the field of programmed cell death research.

Methods and Experimental Design Insights

The study begins with comprehensive data mining using the TCMSP and ETCM databases to identify bioactive components within CIE. Targets related to glioma were retrieved from GeneCards and DisGeNET, and intersected to select overlapping drug-disease targets. Protein-protein interaction (PPI) networks were constructed via the STRING database, enabling the identification of central nodes in glioma signaling. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses highlighted relevant biological processes and pathways.

Cytoscape was employed to visualize compound-target-pathway networks, guiding the selection of compounds for further study. Molecular docking simulations were performed to predict binding affinities between CIE constituents—particularly flavonoids such as kaempferol, naringenin, and luteolin—and key protein targets like AR. Experimental validation included cell-based assays to measure proliferation, migration, and apoptosis in rat C6 glioma cells, as well as in vivo antitumor activity assessments in animal models.

Protocol Parameters

• Active compound screening: Compounds with high oral bioavailability and drug-likeness metrics were prioritized using TCMSP and ETCM databases.
• Target identification: Drug-disease target overlap was mapped using GeneCards and DisGeNET, followed by PPI analysis in STRING.
• Molecular docking: Binding energies for AR and other key targets with CIE flavonoids were calculated; lower binding energies indicated stronger predicted interactions.
• In vitro assays: C6 glioma cells were treated with CIE at different concentrations to assess proliferation (MTT assay), migration (wound healing assay), and apoptosis (flow cytometry, TUNEL assay).
• In vivo validation: Rat xenograft models were administered CIE, with tumor volume and apoptotic index as primary readouts.

Core Findings and Why They Matter

The reference study identified 23 active compounds within CIE and 130 potential protein targets. Nine key targets were highlighted: ESR1, SIRT1, HSP90AA1, PTGS2, RELA, AR, NOS3, DNMT1, and GSK3B. GO and KEGG analyses indicated CIE’s effects are concentrated in canonical cancer pathways.

Importantly, AR emerged as a central mediator of glioma progression. Molecular docking revealed that kaempferol, naringenin, and luteolin—major CIE flavonoids—bind strongly to AR, suggesting a direct mechanism for CIE’s activity. Experimental validation confirmed that CIE suppresses proliferation and migration of C6 glioma cells, while significantly increasing apoptotic rates. Protein expression analysis further supported these mechanisms, with changes in AR and related pathway proteins observed after CIE treatment. In vivo, CIE reduced tumor growth and enhanced apoptosis in glioma xenograft models.

These findings provide a mechanistic bridge between traditional herbal medicine and targeted cancer therapy, demonstrating that CIE modulates apoptosis and tumor progression via defined protein targets and signaling pathways.

Comparison with Existing Internal Articles

Several comprehensive resources elaborate on the technical aspects of apoptosis detection and workflow optimization. For example, "Translating Mechanistic Insight into Precision Apoptosis" contextualizes DNA fragmentation and TUNEL assay strategies within cancer research, aligning with the reference study’s emphasis on mechanistic validation using apoptosis markers. Similarly, "Applied TUNEL Assay: Workflow, Use Cases, and Troubleshooting Tips" provides actionable guidance for apoptosis assay setup in glioma models, reinforcing the importance of robust DNA fragmentation detection protocols such as those utilized in the CIE study. Workflow-focused resources, such as "Applied TUNEL Apoptosis Detection Kit Workflows & Troubleshooting", bridge the gap between experimental findings and reproducible laboratory practices, supporting the translation of findings from the reference study into standardized research protocols.

Limitations and Transferability

While the study offers valuable mechanistic insights, some limitations are notable. The in vivo experiments were conducted in rat models, and while these provide translational relevance, interspecies differences may affect the applicability of findings to human glioma. The extract contains multiple active compounds with potential for synergistic or antagonistic effects; isolating the contributions of individual components warrants further study. Furthermore, although AR was identified as a central target, the broader network of protein interactions and pathway cross-talk in glioma biology remains complex and incompletely mapped.

Transferability to other cancer types or neurological disorders should be approached cautiously, as the molecular landscape and microenvironmental factors may differ significantly. The study’s integrated approach, however, serves as a methodological template for investigating other botanical extracts or candidate compounds in programmed cell death research.

Research Support Resources

For researchers aiming to replicate or extend these findings, robust apoptosis detection is critical. The TUNEL Apoptosis Detection Kit (DAB) (SKU K2271) from APExBIO offers a reliable workflow for detecting DNA fragmentation in tissue sections and cultured cells, as employed in apoptosis assays throughout the referenced study. Its compatibility with both paraffin-embedded and frozen samples, along with clear HRP-DAB chromogenic readout, facilitates precise quantification of apoptotic cells in glioma and other models. For further workflow optimization and troubleshooting in DNA fragmentation detection, researchers may consult the internal articles cited above.